Showing results (251-260 of 1,283) with videos related to
Sort By:
Pageof 129
Blood|June 14, 2000
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalitiesR Desikan, B Barlogie, J Sawyer, et al.British Journal of Haematology|November 1, 1996
Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myelomaR Govindarajan, S Jagannath, J T Flick, et al.Cancer|May 15, 1991
A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. A Southwest Oncology Group studyC S Higano, J Crowley, R B Livingston, et al.European Journal of Cancer & Clinical Oncology|April 1, 1984
In vitro suppression of DNA synthesis by a remission induction agent and its correlation with response in adult acute leukemiaA M Maddox, D A Johnston, B Barlogie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group studyS E Salmon, J J Crowley, T M Grogan, et al.Cancer|June 1, 1986
Fusarium. A newly recognized fungal pathogen in immunosuppressed patientsE Anaissie, H Kantarjian, P Jones, et al.Blood|August 1, 1986
HLA-DR-associated invariant chain is highly expressed in chronic lymphocytic leukemiaF Narni, J Kudo, W Mars, et al.Blood|February 1, 1986
Treatment of multiple myeloma with recombinant alpha-interferonJ R Quesada, R Alexanian, M Hawkins, et al.Leukemia|March 11, 2015
The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myelomaX Papanikolaou, D Alapat, A Rosenthal, et al.Blood|May 16, 1998
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiationM V Dhodapkar, E Abe, A Theus, et al.Pageof 129